A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF
- 18 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Assisted Reproduction and Genetics
- Vol. 37 (5), 1163-1170
- https://doi.org/10.1007/s10815-020-01742-5
Abstract
Objective To assess whether corifollitropin-α (CFα) late-start administration (day 4) and standard administration (day 2) can obtain similar oocyte yield and live birth rate. Study design A randomized controlled trial. Setting University Hospital IVF Unit. Patients One hundred thirteen women undergoing IVF. Interventions Patients distributed in three subgroups (expected poor, normal, or high responders to FSH) were randomized into two treatment arms: (a) CFα late-start: CFα on day 4 + GnRH antagonist from day 8 + (when needed) recFSH from day 11; (b) CFα standard start: CFα on day 2 + GnRH antagonist from day 6 + (when needed) recFSH from day 9. IVF or ICSI was performed as indicated. Results Considering the whole study group, the late-start regimen obtained comparable oocyte yield (8.9 ± 5.6 vs. 8.8 ± 6.2; p = n.s.), cPR/started cycle (25% vs. 31.6%, p = n.s.), and cumulative live birth rate (LBR)/ovum pickup (OPU) (29.2% vs. 37.7%, p = n.s.) than the standard regimen. The outcome of the two regimens was comparable in the two subgroups of high and normal responders. Differently, in poor responders, oocyte yield was similar, but LBR/OPU was significantly lower with late-start CFα administration that caused 40% cancellation rate due to monofollicular response. ROC curves showed that the threshold AMH levels associated with cycle cancellation were 0.6 ng/ml for late-start regimen and 0.2 ng/ml for standard regimen. Conclusion CFα may be administered on either day 2 or day 4 to patients with expected high or normal response to FSH without compromising oocyte yield and/or live birth rate. Differently, late-start administration is not advisable for expected poor responders with AMH ≤ 0.6 ng/ml. Trial registration NCT03816670Keywords
This publication has 24 references indexed in Scilit:
- Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case–control studyJournal of Assisted Reproduction and Genetics, 2015
- Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: A randomized controlled pilot studyHuman Reproduction, 2014
- Polarized light microscopy-detectable structures of human oocytes and embryos are related to the likelihood of conception in IVFJournal of Assisted Reproduction and Genetics, 2012
- When and why do subfertile couples discontinue their fertility care? A longitudinal cohort study in a secondary care subfertility populationHuman Reproduction, 2009
- Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequencyHuman Reproduction Update, 2009
- Mild ovarian stimulation for IVFHuman Reproduction Update, 2008
- A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trialThe Lancet, 2007
- Towards a more physiological approach to IVFReproductive BioMedicine Online, 2007
- Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides.Endocrinology, 1992
- Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.Proceedings of the National Academy of Sciences of the United States of America, 1992